Spero

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Monday, July 11, 2022
FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, HBR, Defendant, Treatment, Superior, Mission statement, Review, New Drug Application, GLOBE, Degenerative disease, Medicare, Lists of schools in England, Spero, Plaque, News, Population, NDA, Class Action, LMP, Tebipenem, Marketing, Government, Income, Relevant, Patient, SEC, Growth, Complicated, Physician, California superior courts, XRAY, Infection, Annual report, Urinary tract infection, Audit committee, CDNA, Justice, Food, Company, ASP, Dentsply Sirona, Anesthetic, Workforce, Kidney, COVID-19, Risk, Sale, Board, Documentation, NASDAQ, Complaint, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, Pyelonephritis, P.C

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Spero Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, July 10, 2022
Titan, FDA, I-Space (Chinese company), Urinary tract infection, Advertising, LinkedIn, Court, New Drug Application, TO, WHY, Workforce, Food and Drug Administration, GLOBE, Class, Pyelonephritis, Tebipenem, Lists of schools in England, Food, THE, Spero, Facebook, NASDAQ, Twitter, NDA, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • Rosen Law Firm has achieved the largest ever securities class action settlement against a Chinese Company.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Saturday, July 9, 2022
Review, FDA, Urinary tract infection, Patient, Securities Exchange Act of 1934, Treatment, Court, Infection, LLP, Workforce, GLOBE, Population, Degenerative disease, Company, District court, Complicated, Tebipenem, Lists of schools in England, Pomerantz, Ext, Food, Person, HBR, Lists of action films, Complaint, New Drug Application, NASDAQ, SEC Rule 10b-5, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Spero Therapeutics, Inc. (SPRO)

Retrieved on: 
Wednesday, July 6, 2022
Review, FDA, Defendant, Court, Therapy, Workforce, GLOBE, Company, Suite, Tebipenem, Lists of schools in England, Food, HBR, GPM, Urinary tract infection, New Drug Application, NASDAQ, Time, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Medical device, Pharmaceutical industry, Spero

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • On this news, Speros stock fell $1.59, or 18.27%, to close at $7.11 per share on April 1, 2022.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Tuesday, July 5, 2022
XRAY, Urinary tract infection, Patient, Treatment, GLOBE, Marketing, COVID-19, Growth, Degenerative disease, Company, Complicated, Annual report, CDNA, Food, Mission statement, HBR, Class Action, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, FDA, Population, Tebipenem, Plaque, Dentsply Sirona, SEC, Income, Documentation, Defendant, Workforce, Kidney, New Drug Application, NASDAQ, Board, Medicare, News, ASP, Complaint, Review, California superior courts, Justice, Audit committee, Infection, Sale, Lists of schools in England, Relevant, Risk, LMP, Superior, Spero, Anesthetic, Government, Physician, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages Spero Therapeutics, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – SPRO

Retrieved on: 
Sunday, July 3, 2022
Titan, FDA, I-Space (Chinese company), Urinary tract infection, Advertising, LinkedIn, Court, New Drug Application, TO, WHY, Workforce, Food and Drug Administration, GLOBE, Class, Pyelonephritis, Tebipenem, Lists of schools in England, Food, THE, Spero, Facebook, NASDAQ, Twitter, NDA, Medical device, Insurance, Tobacco

WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.

Key Points: 
  • WHAT TO DO NEXT: To join the Spero Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=6561 or call Phillip Kim, Esq.
  • WHY ROSEN LAW: We encourage investors to select qualified counsel with a track record of success in leadership roles.
  • The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
  • 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Spero Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadline – SPRO

Retrieved on: 
Friday, July 1, 2022
Review, FDA, Urinary tract infection, Patient, Securities Exchange Act of 1934, Treatment, Court, Infection, LLP, Workforce, GLOBE, Population, Degenerative disease, Company, District court, Complicated, Tebipenem, Lists of schools in England, Pomerantz, Ext, Food, Person, HBR, Lists of action films, Complaint, New Drug Application, NASDAQ, SEC Rule 10b-5, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Renewable energy, Spero, Pyelonephritis

To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.

Key Points: 
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • On March 31, 2022, Spero issued a press release announcing the Companys fourth quarter and full year 2021 financial results.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against CareDx, Spero, LMP, and Dentsply Sirona and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, June 30, 2022
XRAY, Urinary tract infection, Patient, Treatment, GLOBE, Marketing, COVID-19, Growth, Degenerative disease, Company, Complicated, Annual report, CDNA, Food, Mission statement, HBR, Class Action, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, FDA, Population, Tebipenem, Plaque, Dentsply Sirona, SEC, Income, Documentation, Defendant, Workforce, Kidney, New Drug Application, NASDAQ, Board, Medicare, News, ASP, Complaint, Review, California superior courts, Justice, Audit committee, Infection, Sale, Lists of schools in England, Relevant, Risk, LMP, Superior, Spero, Anesthetic, Government, Physician, Pharmaceutical industry, Animal, Renewable energy, Audit, Medical device, Property management, P.C, Pyelonephritis

Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.

Key Points: 
  • Throughout the Class Period, CareDx reported growing revenue and strong demand in the Companys testing services segment.
  • In order to facilitate this scheme, Dentsply and its executives made numerous false and misleading statements to investors during the Class Period.
  • For more information on the Dentsply Sirona class action go to: https://bespc.com/cases/XRAY
    About Bragar Eagel & Squire, P.C.
  • The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country.

Spero Therapeutics Receives Complete Response Letter from U.S. Food and Drug Administration for Tebipenem HBr New Drug Application

Retrieved on: 
Monday, June 27, 2022
Review, FDA, Assistant, CRL, Patient, Adult, Research, Infection, Cutis verticis gyrata, Biomedical Advanced Research and Development Authority, Therapy, Endpoint security, Trial of the century, GLOBE, COVID-19, Pyelonephritis, Degenerative disease, Program, U.S. Securities and Exchange Commission, Tebipenem, Risk, Food, Partnership, HBR, Nasdaq, Urinary tract infection, Human services, Preparedness, New Drug Application, PDUFA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, NDA, Pharmaceutical industry, Medical device, Vaccine, Spero

The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022.

Key Points: 
  • The FDA had set a Prescription Drug User Fee Act (PDUFA) target action date of June 27, 2022.
  • In the CRL, the FDA ultimately concluded that Speros Phase 3 cUTI study of tebipenem HBr (ADAPT-PO) was insufficient to support approval and that additional clinical study would be required.
  • Spero intends to promptly request a Type A meeting with the FDA, to gain further insights as to the pathway forward towards a potential regulatory approval for tebipenem HBr.
  • Tebipenem HBr is an investigational drug in the United States being developed for the treatment of cUTI, including pyelonephritis, caused by certain microorganisms, in adult patients who have limited treatment options; tebipenem HBr is not FDA-approved.

Spero Therapeutics, Inc. Investors: Class action lawsuit filed on behalf of investors; the Portnoy Law Firm

Retrieved on: 
Monday, June 27, 2022
Workforce, Review, GLOBE, FDA, Tebipenem, NASDAQ, Company, NDA, Lists of schools in England, Pharmaceutical industry, Spero

LOS ANGELES, June 27, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors. Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.

Key Points: 
  • LOS ANGELES, June 27, 2022 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Spero Therapeutics, Inc. ("Spero" or the "Company") (NASDAQ: SPRO) investors that a class action filed on behalf of investors.
  • Spero investors that lost money on their investment are encouraged to contact Lesley Portnoy, Esq.
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors options for pursuing claims to recover their losses.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.